pembrolizumab + telaglenastat

**pembrolizumab + telaglenastat** is an investigational drug combination for the treatment of certain cancers, notably non-small cell lung cancer (NSCLC) with KEAP1/NRF2 mutations. Pembrolizumab is a monoclonal antibody targeting PD-1, acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Telaglenastat is a first-in-class glutaminase inhibitor that blocks cancer cells from using glutamine for growth and survival by inhibiting the enzyme glutaminase[4][3][7]. The combination aims to improve outcomes in patients with tumors that are highly dependent on glutamine metabolism and resistant to standard therapies.